This week Eagle Biosciences is highlighting a revolutionary test in the microbiome industry. The GA-map® Dysbiosis Test Lx was developed by Genetic Analysis in Norway. The GA-map ® is a tool that allows mapping of the intestinal microbiota profile for a selected set of bacteria in a sample. The test is based on advances in DNA profiling using probes targeting variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by professor Knut Rudi of the Norwegian University of Life Sciences (NMBU) (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine the microbiota profile in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.
Check out this video for a quick overview of the GA-map ® Dysbiosis Test Lx Platform equipment and techniques.